CD200R1 and melanoma: Given that CD200R-deficiency or anti-CD200 treatment leads to reduced T cell responses and fails to show benefits either alone or in combination with checkpoint inhibitors, blockade of CD200 should not be considered for immunotherapy of cancers such as melanoma.